Hepatitis C after liver transplantation: Risk factors, outcomes, and treatment

Current Opinion in Organ Transplantation

Volumn 10, Issue 2, 2005, Pages 81-89

  Berenguer, Marina ^a  

^a HOSPITAL UNIVERSITARIO LA FE   (Spain)

Author keywords

Cytomegalovirus; Donor; Fibrosing cholestatic hepatitis; Hepatitis C virus; Immunosuppression; Interferon; Live donor liver transplantation; Liver fibrosis; Liver steatosis; Liver transplantation; Natural history; Pegylated interferon; Rejection; Ribavirin

Indexed keywords

ALEMTUZUMAB; ANTIVIRUS AGENT; AZATHIOPRINE; CALCINEURIN INHIBITOR; CYCLOSPORIN A; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 2 RECEPTOR ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; PEGINTERFERON; PREDNISONE; RAPAMYCIN; RIBAVIRIN; STEROID; TACROLIMUS;

AGE; DISEASE ASSOCIATION; DISEASE COURSE; DONOR; HEPATITIS C; HUMAN; IMMUNE DEFICIENCY; IMMUNOSUPPRESSIVE TREATMENT; INFECTION RISK; LIVER TRANSPLANTATION; OUTCOMES RESEARCH; PATIENT SELECTION; POSTOPERATIVE INFECTION; RECURRENT INFECTION; REVIEW;

EID: 21044439193     PISSN: 10872418     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mot.0000161761.40866.12     Document Type: Review

References (77)

1. Berenguer M, Lopez-Labrador FX, Wright TL. Hepatitis C and liver transplantation. J Hepatol 2001; 35:666-678.
2. Wiesner RH, Sorrell M, Villamil F. Report of the First International Liver Transplant Society Consensus Conference on Liver Transplantation and Hepatitis C. Liver Transpl 2003; 9(suppl 3):S1-S9.
3. Gane E. The natural history and outcome of liver transplantation in hepatitis C virus-infected recipients. Liver Transpl 2003; 9(suppl 3):S28-S34.
4. Berenguer M, Prieto M, San Juan F, et al. Contribution of donor age to the recent decrease in patient survival among HCV-infected liver transplant recipients. Hepatology 2002; 36:202-210.
5. Berenguer M, Crippin J, Gish R, et al. A model to predict severe HCV-related disease following liver transplantation. Hepatology 2003; 38:34-41.
6. Neumann UP, Berg T, Bahra M, et al. Long-term outcome of liver transplants for chronic hepatitis C: a 10-year follow-up. Transplantation 2004; 77:226-231. One of the first large studies assessing outcome of HCV-infected recipients at 10 years after transplantation, confirming the lower survival rate compared with HCV-negative patients, due in large part to HCV allograft failure (36% of all deaths); the negative impact of donor age (>40) on graft/patient survival; and the negative impact of pulse steroids/OKT3 on HCV progression.
7. Casanova-Taltavull T, Ercilla MG, Gonzalez CP, et al. Long-term immune response after liver transplantation in patients with spontaneous or post-treatment HCV-RNA clearance. Liver Transpl 2004; 10:584-594. This study confirms that spontaneous or drug-induced viral eradication has a strong multispecific immune response. The opposite is true for those with persistent infection.
8. Garcia-Retortillo M, Forns X, Feliu A, et al. Hepatitis C virus kinetics during and immediately after liver transplantation. Hepatology 2002; 35:680-687.
9. Ballardini G, De Raffele E, Groff P, et al. Timing of reinfection and mechanisms of hepatocellular damage in transplanted hepatitis C virus-reinfected liver. Liver Transpl 2002; 8:10-20.
10. Charlton M. Liver biopsy, viral kinetics, and the impact of viremia on severity of hepatitis C virus recurrence. Liver Transpl 2003; 9(Suppl 3):S58-S62.
11. Zekry A, Gleeson M, Turhan S, McCaughan GW. The effect of mycophenolate compared to azathioprine on viral load in HCV liver transplant recipients. Liver Transpl 2004; 10:52-58. A prospective crossover study demonstrating increase in viral load in HCV transplant recipients 3 months after switching from azathioprine to mycophenolate mofetil.
12. Watashi K, Hijikata M, Hosaka M, et al. Cyclosporin A suppresses replication of hepatitis C virus genome in cultured hepatocytes. Hepatology 2003; 38:1282-1288.
13. Stangl JR, Carroll KL, Illichmann M, Striker R. Effect of antimetabolite immunosuppressants on flaviviridae, including hepatitis C virus. Transplantation 2004; 77:562-567. An antiviral effect of azathioprine is suggested in this in-vitro study.
14. McCaughan GW, Zekry A. Mechanisms of HCV reinfection and allograft damage after liver transplantation. J Hepatol 2004; 40:368-374. An excellent review of the mechanisms of allograft damage due to recurrent HCV emphasising the different patterns of recurrence.
15. Wali M, Harrison RF, Gow PJ, Mutimer D. Advancing donor liver age and rapid fibrosis progression following transplantation for hepatitis C. Gut 2002; 51: 248-252.
16. Firpi RJ, Abdelmalek MF, Soldevila-Pico C, et al. One-year protocol liver biopsy can stratify fibrosis progression in liver transplant recipients with recurrent hepatitis C infection. Liver Transpl 2004; 10:1240-1247. This study confirms prior studies demonstrating the accelerated fibrosis progression in HCV-infected transplant recipients, the negative impact of donor age, and the usefulness of the 1-year liver biopsy in predicting progressive disease.
17. Machicao VI, Bonatti H, Krishna M, et al. Donor age affects fibrosis progression and graft survival after liver transplantation for hepatitis C. Transplantation 2004; 77:84-92. In this large study, where old-donor allografts (>50 years) constituted 49% of the donor pool, severe fibrosis at 12 months was observed in 26% of old-donor recipients but in only 13% of young-donor recipients, again emphasising the importance of the age of the donor for HCV-infected patients.
18. Neumann UP, Berg T, Bahra M, et al. Fibrosis progression after liver transplantation in patients with recurrent hepatitis C. J Hepatol 2004; 41:830-836. This study describes the rate of HCV fibrosis progression in the long term following liver transplantation, showing an exponential increase during the first 3 years followed by a stabilisation in the long term. Donor age and genotype 1 and 4 predicted accelerated fibrosis progression. The stage of fibrosis at 1 year was extremely useful in predicting long-term outcome.
19. Berenguer M, Aguilera V, Prieto M, et al. Delayed onset of severe hepatitis C-related liver damage following liver transplantation: a matter of concern? Liver Transpl 2003; 1152-1158.
20. Berenguer M, Prieto M, Rayón JM, et al. Natural history of clinically compensated HCV-related graft cirrhosis following liver transplantation. Hepatology 2000; 32:852-858.
21. Forman LM, Dewis JD, Berlin JA, et al. The association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology 2002; 122:889-896.
22. Burak KW, Kremers WK, Batts KP, et al. Impact of cytomegalovirus infection, year of transplantation, and donor age on outcomes after liver transplantation for hepatitis C. Liver Transpl 2002; 8:362-369.
23. Regev A, Molina E, Moura R, et al. Reliability of histopathologic assessment for the differentiation of recurrent hepatitis C from acute rejection after liver transplantation. Liver Transpl 2004; 10:1233-1239. In this study, the intraobserver and interobserver agreement rates for differentiating acute cellular rejection from recurrent hepatitis C were relatively low among five experienced liver pathologists.
24. Lake JR. The role of immunosuppression in recurrence of hepatitis C. Liver Transpl 2003; 9:S63-S66.
25. Berenguer M. What determines the natural history of recurrent hepatitis C after liver transplantation. J Hepatol 2005; 42:448-456.
26. Brillanti S, Vivarelli M, De Ruvo N, et al. Slowly tapering off steroids protects the graft against hepatitis C recurrence after liver transplantation. Liver Transpl 2002; 8:884-888.
27. Jain A, Kashyap R, Demetris AJ, et al. A prospective randomized trial of mycophenolate mofetil in liver transplant recipients with hepatitis C. Liver Transpl 2002; 8:40-46.
28. Fasola CG, Netto GJ, Christensen LL, et al. Lower incidence of early HCV RNA levels and HCV recurrence post-liver transplantation in patients induced with mycophenolate mofetil: a high-dose benefit. Am J Transplant 2002; 2:196.
29. Marcos A, Eghtesad B, Fung JJ, et al. Use of alemtuzumab and tacrolimus monotherapy for cadaveric liver transplantation: with particular reference to hepatitis C virus. Transplantation 2004; 78:966-971.
30. Martin P, Busuttil RW, Goldstein RM, et al. Impact of tacrolimus versus cyclosporine in hepatitis C virus-infected liver transplant recipients on recurrent hepatitis C: a prospective randomized trial. Liver Transpl 2004; 10:1258-1262. In this prospective study comparing cyclosporine microemulsion with tacrolimus in HCV recipients, the outcome was similar in terms of survival but levels of viremia were higher in the cyclosporine group.
31. Fung J, Eghtesad B, Patel-Tom K, et al. Liver transplantation in patients with HIV infection. Liver Transpl 2004; 10:S39-S53.
32. Berenguer M, Prieto M, Palau A, et al. Severe recurrent hepatitis C following liver retransplantation for HCV-related graft failure. Liver Transpl 2003; 9: 228-235.
33. Burton JR, Sonnenberg A, Rosen HR. Retransplantation for recurrent hepatitis C in the MELD era: maximising utility. Liver Transpl 2004; 10(suppl 2): S59-S64. An excellent review/study of liver retransplantation for recurrent hepatitis C showing that utility of retransplantation starts to decline at MELD (model for end-stage liver disease) scores above 28, and hence, that the current allocation system (MELD) fails to maximise utility with regard to this indication.
34. Neff GW, O'Brien C, Nery J, et al. Factors that identify survival after liver retransplantation for allograft failure caused by recurrent hepatitis C infection. Liver Transpl 2004; 10:1497-1503. In this study, HCV was again found as a major factor predicting lower survival after retransplantation due to the development of chronic graft destruction of the second graft.
35. Arenas JI, Gallegos-Orozco JF, Laskus T, et al. Hepatitis C quasi-species dynamics predict progression of fibrosis after liver transplantation. J Infect Dis 2004; 189:2037-2046. In this study on HCV heterogeneity, a less complex quasispecies composition prior to transplantation was associated with a more severe posttransplant HCV disease.
36. Lopez-Labrador FX, Berenguer M, Sempere A, et al. Genetic variability of hepatitis C virus NS3 protein in human leukocyte antigen-A2 liver transplant recipients with recurrent hepatitis C. Liver Transpl 2004; 10:217-227. Different HCV-1b strains may exist with different pathogenicity and increased fibrosis progression after liver transplantation.
37. Toniutto P, Fabris C, Bortolotti N, et al. Evaluation of donor hepatic iron concentration as a factor of early fibrotic progression after liver transplantation. J Hepatol 2004; 41:307-311. The first study to assess the effect of hepatic iron concentration on recurrent fibrosis progression.
38. Machicao VI, Krishna M, Bonatti H, et al. Hepatitis C recurrence is not associated with allograft steatosis within the first year after liver transplantation. Liver Transpl 2004; 10:599-606. The incidence of allograft steatosis within the first-year liver biopsies was similar in HCV and non-HCV recipients. In addition, steatosis did not predict HCV disease severity at 1 year after transplantation.
39. Ghobrial RM, Gornbein J, Steadman R, et al. Pretransplant model to predict posttransplant survival in liver transplant patients. Ann Surg 2002; 236:315-322.
40. Charlton M, Ruppert K, Belle SH, et al. Long-term results and modeling to predict outcomes in recipients with HCV infection: results of the NIDDK liver transplantation database. Liver Transpl 2004; 10:1120-1130. In this study based on the National Institute of Diabetes and Digestive and Kidney Diseases liver transplantation database, survival was not different in HCV-positive and HCV-negative recipients. The major cause of late death or graft loss was recurrence of HCV. Pretransplantation variables associated with early mortality were reflective of poor overall recipient immunity (cytomegalovirus IgG seronegativity, higher HCV titres, donor and recipient age) and general debility (higher international normalised ratio, bilirubin, creatinine). None of theses variables were significantly associated with long-term outcome.
41. Gaglio PJ, Malireddy S, Levitt BS, et al. Increased risk of cholestatic hepatitis C in recipients of grafts from living versus cadaveric liver donors. Liver Transpl 2003; 39:1028-1035.
42. Van Vlierberghe H, Troisi R, Colle I, et al. Hepatitis C infection-related liver disease: patterns of recurrence and outcome in cadaveric and living donor liver transplantation in adults. Transplantation 2004; 77:210-214.
43. Rodriguez-Luna H, Vargas HE, Sharma P, et al. Hepatitis C virus recurrence in living donor liver transplant recipients. Dig Dis Sci 2004; 49:38-41. One study showing no differences at 1 year between live-donor and deceased-donor liver transplantation in terms of viremia, histology, or survival.
44. Russo MW, Galanko J, Beavers K, et al. Patient and graft survival in hepatitis C recipients after adult living donor liver transplantation in the United States. Liver Transpl 2004; 10:340-346. In this study based on the United Network for Organ Sharing, short-term patient and graft survival rates were similar between live-donor and deceased-donor liver transplant recipients.
45. Bozorgzadeh A, Jain A, Ryan C, et al. Impact of hepatitis C viral infection in primary cadaveric liver allograft versus primary living donor allograft in 100 consecutive liver transplant recipients receiving tacrolimus. Transplantation 2004; 77:1066-1090.
46. Garcia-Retortillo M, Forns X, Llovet JM, et al. Hepatitis C recurrence is more severe after living donor compared to cadaveric liver transplantation. Hepatology 2004; 40:699-707. A study based on protocol liver biopsies suggesting that hepatitis C is more aggressive following LDLT compared with cadaveric liver transplantation.
47. Shiffman ML, Stravitz RT, Contos M, et al. Histologic analysis of recurrent hepatitis C virus infection following living donor and cadaveric liver transplantation. Liver Transpl 2004; 10:1248-1255. In this study on the natural history of recurrent HCV, the type of surgery (live-donor vs deceased-donor liver transplantation) had no effect on survival nor on the rate of severe recurrent HCV based on protocol liver biopsies.
48. Rimola A, Londoño MC, Guevara G, et al. Beneficial effect of angiotensin-blocking agents on graft fibrosis in hepatitis C recurrence after liver transplantation. Transplantation 2004; 78:686-691. The potential benefit of using angiotensin-blocking agents against HCV fibrosis progression of the graft is described in this study.
49. Filipponi F, Callea F, Salizzoni M, et al. Double-blind comparison of hepatitis C histological recurrence rate in HCV + liver transplant recipients given basiliximab + steroids or basiliximab + placebo, in addition to cyclosporin and azathioprine. Transplantation 2004; 78:1488. A randomised study evaluating monoclonal antibodies against interleukin-2R for the prevention of rejection in hepatitis C recipients. The results, worse outcome with quadruple therapy (interleukin-2R monoclonal antibody + cyclosporine + azathioprine + steroids) is a warning against too much immunosuppression in HCV-infected recipients.
50. McGaughan GW. Immunosuppression for HCV following liver transplantation: enough is just enough. Transplantation 2004; 78:1413-1414.
51. Everson GT. Treatment of patients with hepatitis C virus on the waiting list. Liver Transpl 2003; 9(suppl 3):S90-S94.
52. Bizollon T, Admed SNS, Radenne S, et al. Long-term histologic improvement and clearance of intrahepatic hepatitis C virus RNA following sustained response to interferon-ribavirin combination therapy in liver transplant patients with hepatitis C recurrence. Gut 2003; 52:283-287.
53. Abdelmalek MF, Firpi RJ, Soldevila-Pico C, et al. Sustained viral response to interferon and ribavirin in liver transplant recipients with recurrent hepatitis C. Liver Transpl 2004; 10:199-207. This study demonstrates that a sustained virologic response following antiviral therapy for recurrent hepatitis C is durable in the long term and is associated with improvement in hepatic inflammation and regression of fibrosis on histology.
54. Forns X, Garcia-Retortillo M, Serrano T, et al. Antiviral therapy of patients with decompensated cirrhosis to prevent recurrence of hepatitis C after liver transplantation. J Hepatol 2003; 39:389-396.
55. Crippin JS, Sheiner P, Terrault NA, et al. A pilot study of the tolerability and efficacy of antiviral therapy in patients awaiting liver transplantation for hepatitis C. Liver Transpl 2002; 8:350-355.
56. Thomas RM, Brenns JJ, Guzmán-Hartman G, et al. Infection with chronic hepatitis C virus and liver transplantation: a role for interferon therapy before transplantation. Liver Transpl 2003; 9:905-915.
57. Terrault NA. Prophylactic and preemptive therapies for hepatitis C virus infected patients undergoing liver transplantation. Liver Transpl 2003; 9:S95-S100.
58. Chalasani N, Manzarbeitia C, Ferenci P, et al. Peginterferon alfa 2a for recurrence of hepatitis C after liver transplantation: two randomised, controlled trials. Hepatology 2005; 41:289-298. Two prospective studies evaluating the efficacy and tolerability of monotherapy with pegylated interferon-α2a used either preemptively or in the context of established recurrent disease. The low efficacy is discussed.
59. Shergill AK, Khalili M, Straley S, et al. Applicability, tolerability and efficacy of preemptive antiviral therapy in hepatitis C infected patients undergoing liver transplantation. Am J Transplant 2005; 5:118-124. One of the first prospective studies on preemptive antiviral therapy demonstrating its low applicability, particularly in 'sicker patients', and the low efficacy likely related to the poor tolerability that makes the achievement of target drug doses difficult.
60. Berenguer M. Treatment of hepatitis C after liver transplantation. Clin Liver Dis 2005. (in press)
61. Alberti AB, Belli LS, Airoldi A, et al. Combined therapy with interferon and low-dose ribavirin in posttransplantation recurrent hepatitis C: a pragmatic study. Liver Transpl 2001; 7:870-876.
62. Firpi RJ, Abdelmalek MF, Soldevila-Pico C, et al. Combination of interferon alfa-2b and ribavirin in liver transplant recipients with histological recurrent hepatitis C. Liver Transpl 2002; 8:1000-1006.
63. Lavezzo B, Franchello A, Smedile A, et al. Treatment of recurrent hepatitis C in liver transplants: efficacy of a six versus twelve month course of interferon alfa 2b with ribavirin. J Hepatol 2002; 37:247-252.
64. Samuel D, Bizollon T, Feray C, et al. Interferon-alpha 2b plus ribavirin in patients with chronic hepatitis C after liver transplantation: a randomized study. Gastroenterology 2003; 124:642-650.
65. Giostra E, Kullak-Ublick GA, Keller W, et al. Ribavirin/interferon-alfa sequential treatment of recurrent hepatitis C after liver transplantation. Transpl Int 2004; 17:169-176.
66. Berenguer M, Prieto M, Palau A, et al. Recurrent hepatitis C genotype 1b following liver transplantation (OLT): treatment with combination interferon-ribavirin therapy (CT). Eur J Gastroenterol Hepatol 2005. (in press)
67. Ross AS, Bhan AK, Pascual M, et al. Pegylated interferon alfa-2b plus ribavirin in the treatment of post-liver transplant recurrent hepatitis C. Clin Transplant 2004; 18:166-173.
68. Dumortier J, Scoaxec JY, Chevallier P, Boillot O. Treatment of recurrent hepatitis C after liver transplantation: a pilot study of peginterferon alfa 2b and ribavirin combination. J Hepatol 2004; 40:669-674. A nonrandomised controlled study on pegylated interferon + ribavirin for the treatment of recurrent hepatitis C, with detailed data on side effects and biochemical, virologic, and histologic response.
69. Rodriguez-Luna H, Khatib A, Sharma P, et al. Treatment of recurrent hepatitis C infection after liver transplantation with combination of pegylated interferon alfa 2b and ribavirin: an open label series. Transplantation 2004; 77:190-194. The first study to evaluate the safety and efficacy of pegylated interferon and ribavirin in patients with recurrent hepatitis C. Despite slightly enhanced efficacy compared with standard interferon - ribavirin, tolerability remains poor.
70. Neff GW, Montalbano M, O'Brien C, et al. Treatment of established recurrent hepatitis C in liver transplant recipients with pegylated interferon alfa-2b and ribavirin therapy. Transplantation 2004; 78:1303-1307. A retrospective review of transplant recipients treated with pegylated interferon + ribavirin showing low tolerability but potential efficacy in prior nonresponders to standard interferon + ribavirin.
71. Neff GW, O'Brien CB, Cirocco R, et al. Prediction of sustained virological response in liver transplant recipients with recurrent hepatitis C virus following combination pegylated interferon alfa2b and ribavirin therapy using tissue hepatitis C virus reverse transcriptase polymerase chain reaction testing. Liver Transpl 2004; 10:595-598. In this study, prediction of sustained virologic response was enhanced by measuring HCV RNA in liver instead of serum. This technique could potentially be used to guide longer therapy durations.
72. Todd-Stravitz R, Shiffman ML, Sanyal AJ, et al. Effects of interferon treatment on liver histology and allograft rejection in patients with recurrent hepatitis C following liver transplantation. Liver Transpl 2004; 10:850-858. The problem of interferon-triggered allograft rejection, including irreversible chronic rejection, is confirmed in this study. In addition, virologic response is not always followed by histologic benefit.
73. Saab S, Kalmaz D, Gajjar NA, et al. Outcomes of acute rejection after interferon therapy in liver transplant recipients. Liver Transpl 2004; 10:859-867. Similar conclusions as in the study by Todd-Stravitz et al. (Liver Transpl 2004; 10:850-858) were reported in this study.
74. Jain AB, Eghtesad B, Venkataramanan R, et al. Ribavirin dose modification based on renal function is necessary to reduce hemolysis in liver transplant patients with hepatitis C virus infection. Liver Transpl 2002; 8:1007-1013.
75. Gopal DV, Rosen HR. Duration of antiviral therapy for cholestatic HCV recurrence may need to be indefinite. Liver Transpl 2003; 9:348-353.
76. Saab S, Ly D, Han SB, et al. Is it cost-effective to treat recurrent hepatitis C infection in orthotopic liver transplantation patients? Liver Transpl 2002; 8:449-457.
77. Benlloch S, Berenguer M, Aguilera V, et al. Prediction of fibrosis in HCV-infected liver transplant recipients with a simple non-invasive index. Liver Transpl 2005. (in press)